局部应用重组人Ⅲ型胶原蛋白水凝胶对糖尿病患者创面愈合的影响

doi:10.3877/cma.j.issn.1673-9450.2022.05.009

中华损伤与修复杂志(电子版) ›› 2022, Vol. 17 ›› Issue (05) : 430 -434. doi: 10.3877/cma.j.issn.1673-9450.2022.05.009

论著

局部应用重组人Ⅲ型胶原蛋白水凝胶对糖尿病患者创面愈合的影响

黄晓罡¹, 牛东升², 闫香果¹, 张克松³, 何军民³, 王晓军³, 刘媛媛⁴^,^†(

)

^1. 100093　北京市化工职业病防治院医疗部，综合内科/医务科
^2. 100093　北京市化工职业病防治院职防部，职业卫生科
^3. 100093　北京市化工职业病防治院医疗部，血管外科
^4. 100039　北京，解放军医学院

收稿日期:2022-07-03 出版日期:2022-10-01
通信作者: 刘媛媛

Effect of topical application of recombinant human type-Ⅲ collagen hydrogels on diabetic wound healing

Xiaogang Huang¹, Dongsheng Niu², Xiangguo Yan¹, Kesong Zhang³, Junmin He³, Xiaojun Wang³, Yuanyuan Liu⁴^,^†()

^1. Department of Internal Medicine/Medical, Beijing Prevention and Treatment Hospital of Occupational Disease for Chemical Industry, Beijing 100093, China
^2. Department of Occupational Health, Beijing Prevention and Treatment Hospital of Occupational Disease for Chemical Industry, Beijing 100093, China
^3. Department of Vascular Surgery, Beijing Prevention and Treatment Hospital of Occupational Disease for Chemical Industry, Beijing 100093, China
^4. Chinese PLA Medical School, Beijing 100039, China

Received:2022-07-03 Published:2022-10-01
Corresponding author: Yuanyuan Liu

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

黄晓罡, 牛东升, 闫香果, 张克松, 何军民, 王晓军, 刘媛媛. 局部应用重组人Ⅲ型胶原蛋白水凝胶对糖尿病患者创面愈合的影响[J/OL]. 中华损伤与修复杂志(电子版), 2022, 17(05): 430-434.

Xiaogang Huang, Dongsheng Niu, Xiangguo Yan, Kesong Zhang, Junmin He, Xiaojun Wang, Yuanyuan Liu. Effect of topical application of recombinant human type-Ⅲ collagen hydrogels on diabetic wound healing[J/OL]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2022, 17(05): 430-434.

目的

探讨局部应用重组人Ⅲ型胶原蛋白水凝胶治疗糖尿病合并下肢难愈性创面的效果及其对创面炎症反应的影响。

方法

选择2020年9月至2021年6月北京市化工职业病防治院医疗部收治的糖尿病合并下肢难愈性创面患者20例作为研究对象，采用随机数字表法分为试验组与对照组，每组各10例。在实施基础抗糖尿病治疗基础上，试验组局部外敷重组人Ⅲ型胶原蛋白水凝胶，对照组给予常规清创换药治疗，比较2组创面愈合率及创面组织肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、白细胞介素6(IL-6)及基质金属蛋白酶9(MMP-9)水平。

结果

2组患者治疗后创面面积均较治疗前缩小，试验组患者治疗后7、14 d的创面愈合率分别为(34.00±2.53)%、(73.90±13.00)%，明显高于对照组(23.30±3.89)%、(48.30±6.30)%，差异均有统计学意义(t＝1.330、2.640，P<0.05)；治疗后14 d，2组患者创面中TNF-α、IL-1β、IL-6、MMP-9水平较治疗前均降低，差异均有统计学意义(P<0.05)，且试验组患者创面中TNF-α、IL-1β、IL-6、MMP-9的含量[(87.60±8.78)、(71.70±10.30)、(79.80±13.60)、(11.27±2.45)ng/L]均分别低于对照组[(111.60±9.86)、(81.10±8.03)、(96.90±14.50)、(15.05±2.82)ng/L]，差异均有统计学意义(t＝－5.740、－2.260、－2.720、3.200，P<0.05)。

结论

局部应用重组人Ⅲ型胶原蛋白水凝胶治疗糖尿病合并下肢难愈性创面，可有效提高创面愈合率，降低创面炎症反应，临床治疗效果显著。

关键词: 重组人Ⅲ型胶原蛋白, 水凝胶, 伤口愈合, 糖尿病

Objective

To observe the therapeutic effect of recombinant human type-Ⅲ collagen hydrogels on chronic diabetic wounds, and to explore its influence on the expression levels of inflammatory cytokines in wound tissues.

Methods

From September 2020 to June 2021, 20 diabetes mellitus patients with chronic wounds in lower extremities were selected from Beijing Prevention and Treatment Hospital of Occupational Disease for Chemical Industry, and were divided into the experimental group (10 cases) and the control group (10 cases) according to the random number table. In addition to the basic treatment of diabetes and conventional debridement, the experimental group received topical application of recombinant human type-Ⅲ collagen hydrogels. The wound healing rate, expression levels of tumor necrosis factor-α(TNF-α), interleukin 1β(IL-1β), interleukin 6(IL-6)and matrix metalloproteinase-9(MMP-9) were observed and compared.

Results

After treatment, the area of wounds in both groups decreased. The wound healing rate of the treatment group at 7 d and 14 d after treatment were(34.00±2.53)% and (73.90±13.00)%, which were significantly higher than those of the control group[(23.30±3.89)%, (48.30±6.30)%], the differences were statistically significant (t=1.330, 2.640; P<0.05), 14 d after treatment, the expression levels of TNF-α、IL-1β、IL-6 and MMP-9 decreased, and the expression levels of the treatment group [(87.60±8.78), (71.70±10.30), (79.80±13.60), (11.27±2.45) ng/L] were significantly lower than those of the control group [(111.60±9.86), (81.10±8.03), (96.90±14.50), (15.05±2.82) ng/L], the differences were statistically significant(t=-5.740, -2.260, -2.720, 3.200; P<0.05).

Conclusions

The treatment of chronic diabetic wounds by recombinant human type-Ⅲ collagen hydrogels can accelerate wound healing, reduce wound inflammation and result in significant clinical therapeutic effects.

Key words: Recombinant human type-Ⅲ collagen, Hydrogels, Wound healing, Diabetes mellitus

表1 2组糖尿病合并下肢难愈性创面患者一般资料比较

组别	例数(例)	性别(例)		年龄(岁，±s)	体重指数(kg/m²，±s)	HbA1c(%，±s)	创面病程[d，M(Q₁，Q₃)]	创面面积[cm²，M(Q₁，Q₃)]
组别	例数(例)	男	女	年龄(岁，±s)	体重指数(kg/m²，±s)	HbA1c(%，±s)	创面病程[d，M(Q₁，Q₃)]	创面面积[cm²，M(Q₁，Q₃)]
试验组	10	6	4	55.70±6.88	22.58±1.67	9.30±1.15	56(35，100)	21.50(14.25，38.00)
对照组	10	5	5	51.40±8.22	21.90±1.83	9.43±1.02	42(35，100)	26.00(18.75，34.75)
χ²/t/u值		0.202		1.268	0.882	－0.267	26	49
P值		0.653		0.221	0.390	0.792	0.069	0.940

表1 2组糖尿病合并下肢难愈性创面患者一般资料比较

组别	例数(例)	性别(例)		年龄(岁，±s)	体重指数(kg/m²，±s)	HbA1c(%，±s)	创面病程[d，M(Q₁，Q₃)]	创面面积[cm²，M(Q₁，Q₃)]
组别	例数(例)	男	女	年龄(岁，±s)	体重指数(kg/m²，±s)	HbA1c(%，±s)	创面病程[d，M(Q₁，Q₃)]	创面面积[cm²，M(Q₁，Q₃)]
试验组	10	6	4	55.70±6.88	22.58±1.67	9.30±1.15	56(35，100)	21.50(14.25，38.00)
对照组	10	5	5	51.40±8.22	21.90±1.83	9.43±1.02	42(35，100)	26.00(18.75，34.75)
χ²/t/u值		0.202		1.268	0.882	－0.267	26	49
P值		0.653		0.221	0.390	0.792	0.069	0.940

表2 2组糖尿病合并下肢难愈性创面患者治疗后不同时间创面愈合率比较(%，±s)

组别	例数(例)	治疗后7 d	治疗后14 d
试验组	10	34.00±2.53	73.90±13.00
对照组	10	23.30±3.89	48.30±6.30
t值		1.330	2.640
P值		<0.001	<0.001

表2 2组糖尿病合并下肢难愈性创面患者治疗后不同时间创面愈合率比较(%，±s)

组别	例数(例)	治疗后7 d	治疗后14 d
试验组	10	34.00±2.53	73.90±13.00
对照组	10	23.30±3.89	48.30±6.30
t值		1.330	2.640
P值		<0.001	<0.001

表3 2组糖尿病合并下肢难愈性创面患者治疗前及治疗后7 d创面炎症因子水平比较(ng/L，±s)

组别	TNF-α		IL-1β		IL-6		MMP-9
组别	治疗前	治疗后14 d	治疗前	治疗后14 d	治疗前	治疗后14 d	治疗前	治疗后14 d
试验组	143.10±9.10	87.60±8.78^a	99.30±11.60	71.70±10.30^a	118.40±12.98	79.80±13.60^a	23.31±4.48	11.27±2.45^a
对照组	148.90±8.90	111.60±9.86^a	100.80±12.10	81.10±8.03^a	119.80±12.34	96.90±14.50^a	20.48±3.19	15.05±2.82^a
t值	－1.440	－5.740	－0.282	－2.260	－0.237	－2.720	1.630	3.200
P值	0.168	<0.001	0.781	0.036	0.815	0.014	0.121	0.005

表3 2组糖尿病合并下肢难愈性创面患者治疗前及治疗后7 d创面炎症因子水平比较(ng/L，±s)

组别	TNF-α		IL-1β		IL-6		MMP-9
组别	治疗前	治疗后14 d	治疗前	治疗后14 d	治疗前	治疗后14 d	治疗前	治疗后14 d
试验组	143.10±9.10	87.60±8.78^a	99.30±11.60	71.70±10.30^a	118.40±12.98	79.80±13.60^a	23.31±4.48	11.27±2.45^a
对照组	148.90±8.90	111.60±9.86^a	100.80±12.10	81.10±8.03^a	119.80±12.34	96.90±14.50^a	20.48±3.19	15.05±2.82^a
t值	－1.440	－5.740	－0.282	－2.260	－0.237	－2.720	1.630	3.200
P值	0.168	<0.001	0.781	0.036	0.815	0.014	0.121	0.005

[1]	Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2021, 183: 109119.
[2]	Grennan D. Diabetic Foot Ulcers[J]. JAMA, 321(1): 114.
[3]	Buch PJ, Chai Y, Goluch ED. Treating Polymicrobial Infections in Chronic Diabetic Wounds[J]. Clin Microbiol Rev, 2019, 32(2): e00091-18.
[4]	Xu X, Jerca VV, Hoogenboom R . Bio-inspired Hydrogels as Multi-task Anti-icing Hydrogel Coatings[J]. Chem, 2020, 6(4): 820-822.
[5]	Chen Z, Fan D, Shang L. Exploring the potential of the recombinant human collagens for biomedical and clinical applications: a short review[J]. Biomed Mater, 2020, 16(1): 012001.
[6]	Hua C, Zhu Y, Xu W, et al. Characterization by high-resolution crystal structure analysis of a triple-helix region of human collagen type III with potent cell adhesion activity[J]. Biochem Biophys Res Commun, 2019, 508(4): 1018-1023.
[7]	Hu C, Liu W, Long L, et al. Microenvironment-responsive multifunctional hydrogels with spatiotemporal sequential release of tailored recombinant human collagen type III for the rapid repair of infected chronic diabetic wounds[J]. Mater Chem B, 2021, 9(47): 9684-9699.
[8]	刘彤，郑兴锋，李海航，等. 重组人Ⅲ型胶原蛋白水凝胶对猪全层皮肤缺损创面修复的影响[J/CD]. 中华损伤与修复杂志(电子版), 2019, 14(2): 97-102.
[9]	钱荣立. 关于糖尿病的新诊断标准与分型[J]. 中国糖尿病杂志，2000, 8(1): 5-6.
[10]	Carrinho PM, Andreani DIK, Morete VA, et al. A Study on the Macroscopic Morphometry of the Lesion Area on Diabetic Ulcers in Humans Treated with Photodynamic Therapy Using Two Methods of Measurement[J]. Photomed Laser Surg, 2018, 36(1): 44-50.
[11]	Leung A, Crombleholme TM, Keswani SG. Fetal wound healing: implications for minimal scar formation[J]. Curr Opin Pediatr, 2012, 24(3): 371-378.
[13]	Xie H, Chen X , Shen X, et al. Preparation of Chitosan-collagen-alginate Composite Dressing and Its Promoting Effects on Wound Healing[J]. Int J Biol Macromol, 2018, 107(Pt A): 93-104.
[14]	Korkmaz P, Koçak H, Onbaşı K, et al. The Role of Serum Procalcitonin, Interleukin-6, and Fibrinogen Levels in Differential Diagnosis of Diabetic Foot Ulcer Infection[J]. J Diabetes Res, 2018, 2018: 7104352.
[15]	Weigelt C, Rose B, Poschen U, et al. Immune Mediators in Patients With Acute Diabetic Foot Syndrome[J]. Diabetes Care, 2009, 32(8): 1491-1496.
[16]	Yang KC, Ma X, Liu H, et al. Tumor necrosis factor receptor-associated factor 2 mediates mitochondrial autophagy.[J]. Circ Heart Fail, 2015, 8(1): 175-187.
[17]	Lin CJ, Lan YM, Ou MQ, et al. Expression of miR-217 and HIF-1α/VEGF pathway in patients with diabetic foot ulcer and its effect on angiogenesis of diabetic foot ulcer rats[J]. J Endocrinol Invest, 2019, 42(11): 1307-1317.
[18]	Mirza RE, Koh TJ. Contributions of Cell Subsets to Cytokine Production during Normal and Impaired Wound Healing[J]. Cytokine, 2015, 71(2): 409-412.
[19]	Mirza RE, Fang MM, Ennis WJ, et al. Blocking interleukin-1β induces a healing-associated wound macrophage phenotype and improves healing in type 2 diabetes[J]. Diabetes, 2013, 62(7): 2579-2587.
[20]	Weigelt C, Rose B, Poschen U, et al. Immune Mediators in Patients With Acute Diabetic Foot Syndrome[J]. Diabetes Care, 2009, 32(8): 1491-1496.
[21]	Al -Rikabi AHA, Tobin DJ, Riches-Suman K, et al. Dermal fibroblasts cultured from donors with type 2 diabetes mellitus retain an epigenetic memory associated with poor wound healing responses[J]. Sci Rep, 2021, 11(1): 1474.
[22]	Patel S, Maheshwari A, Chandra A. Biomarkers for wound healing and their evaluation[J]. J Wound Care, 2016, 25(1): 46-55.
[23]	Menghini R, Uccioli L, Vainieri E, et al. Expression of tissue inhibitor of metalloprotease 3 is reduced in ischemic but not neuropathic ulcers from patients with type 2 diabetes mellitus[J]. Acta Diabetologica, 2013, 50(6): 907-910.

[1]	曹雯佳, 刘学兵, 罗安果, 钟释敏, 邓岚, 王玉琳, 李赵欢. 超声矢量血流成像对2型糖尿病患者颈动脉壁剪切应力的研究[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(07): 709-717.
[2]	王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[3]	徐志刚, 曹涛, 何亭, 李博奥, 魏婧韬, 张栋梁, 官浩, 杨薛康. 采用抗生素骨水泥治疗糖尿病患者心脏术后胸骨骨髓炎的临床效果观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 498-502.
[4]	刘昌玲, 张金丽, 张志, 李孝建, 汤文彬, 胡逸萍, 陈宾, 谢晓娜. 负载人脂肪干细胞外泌体的甲基丙烯酰化明胶水凝胶对人皮肤成纤维细胞增殖和迁移的影响[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 517-525.
[5]	姜珊, 李湘燕, 田硕涵, 温冰, 何睿, 齐心. 采用优化抗感染治疗模式改善糖尿病足感染预后的临床观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(05): 398-403.
[6]	关丁丁, 李伟, 孔维诗, 包郁露, 孙瑜. 负载干细胞的光交联蛋白基水凝胶在组织工程中应用的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(05): 447-452.
[7]	别瑶, 曹志斌, 辛静, 王健楠, 惠宗光. 应用基质血管成分细胞治疗糖尿病足溃疡的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(05): 453-456.
[8]	孟令凯, 李大勇, 王宁, 王桂明, 张炳南, 李若彤, 潘立峰. 袖状胃切除术对肥胖伴2型糖尿病大鼠的作用及机制研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 638-642.
[9]	李猛, 姜腊, 董磊, 吴情, 贾犇黎. 腹腔镜胃袖状切除术治疗肥胖合并2型糖尿病及脂肪胰的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 554-557.
[10]	严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[11]	周学锋, 董哲毅, 冯哲, 蔡广研, 陈香美. 糖尿病肾脏疾病中西医结合诊疗指南计划书[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 301-305.
[12]	杜军霞, 赵小淋, 王浩然, 高志远, 王曼茜, 万楠熙, 张冬, 丁潇楠, 任琴琴, 段颖洁, 汤力, 朱晗玉. 2 型糖尿病的血液透析患者肠道微生物组学高通量测序分析[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 313-320.
[13]	邱岭, 朱旭丽, 浦坚, 邢苗苗, 吴佳玲. 糖尿病肾病患者肠道菌群生态特点与胃肠道功能障碍的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 453-458.
[14]	李玺, 蔡芸莹, 张永红, 苏恒. 假性软骨发育不全合并1型糖尿病一例[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 518-520.
[15]	王璇, 娜扎开提·尼加提, 雒洋洋, 蒋升. 皮肤晚期糖基化终末产物浓度与2型糖尿病微血管并发症的相关性[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 447-454.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Effect of topical application of recombinant human type-Ⅲ collagen hydrogels on diabetic wound healing

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Effect of topical application of recombinant human type-Ⅲ collagen hydrogels on diabetic wound healing